The market was impressed with a notable increase in full-year guidance.AbbVie (ABBV 3.38%) stock was the cure for what ails a portfolio on Thursday. The sturdy pharmaceutical company was a favorite of investors, who were trading its shares up by nearly 4% in price in late-session action. This occurred in the wake of the company's latest quarterly earnings release published that morning.Sales drops and sales leapsFor its second quarter, AbbVie earned just under $14.5 billion in revenue. That figure was more ...